Document is current
Any future updates will be listed below
-
Authors
Raghavendra, Akshara Singareeka https://orcid.org/0000-0002-6425-4400
Kettner, Nicole M. https://orcid.org/0000-0003-2043-4407
Kwiatkowski, Danielle
Damodaran, Senthil
Wang, Yan https://orcid.org/0000-0001-9566-8975
Ramirez, David
Gombos, Dan S.
Hunt, Kelly K. https://orcid.org/0000-0001-9156-8723
Shen, Yu https://orcid.org/0000-0002-3899-7868
Keyomarsi, Khandan https://orcid.org/0000-0002-5440-0849
Tripathy, Debu https://orcid.org/0000-0002-5711-2404
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RP170079)
Cancer Prevention and Research Institute of Texas (RP180712)
Cancer Prevention and Research Institute of Texas (RP180712)
Cancer Prevention and Research Institute of Texas (RP170079)
Cancer Prevention and Research Institute of Texas (RP180712)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA255960)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA223772)
- License Information
-
More Information
Article History
Received: 14 August 2024
Accepted: 13 January 2025
First Online: 26 January 2025
Competing interests
: D.T.: Quantum Leap Healthcare. K.K.H.: Armada Health, AstraZeneca, Cairn Surgical, Eli Lilly & Co, Lumicell. K.K.: Apeiron, BluePrint, REPARE, Schrodinger and Novartis. The authors declare no competing interests.
